4.5 Review

Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report

期刊

ACTA PSYCHIATRICA SCANDINAVICA
卷 130, 期 5, 页码 354-363

出版社

WILEY
DOI: 10.1111/acps.12305

关键词

bipolar disorder; clinical aspects; early intervention

资金

  1. AstraZeneca
  2. Eli Lilly
  3. Servier
  4. CNPq
  5. CAPES
  6. NARSAD
  7. Stanley Medical Research Institute
  8. Lundbeck
  9. Sanofi-Aventis
  10. Astra Zeneca
  11. BMS-Otsuka
  12. GSK
  13. Jansen-Cilag
  14. Adamed
  15. Alexza
  16. Almirall
  17. Bial
  18. Bristol-Myers Squibb
  19. Elan
  20. Ferrer
  21. Forest Research Institute
  22. Gedeon Richter
  23. Glaxo-Smith-Kline
  24. Janssen-Cilag
  25. Jazz, Johnson Johnson
  26. Merck
  27. Novartis
  28. Organon
  29. Otsuk
  30. Pfizer
  31. Pierre-Fabre
  32. Qualigen
  33. Roche
  34. Shering-Plough
  35. Shire
  36. Solvay
  37. Sunovion
  38. Takeda
  39. Teva
  40. Spanish Ministry of Science and Innovation (CIBERSAM)
  41. Seventh European Framework Programme (ENBREC)
  42. United Biosource Corporation
  43. Wyeth
  44. NIH
  45. Cooperative Research Centre
  46. Simons Autism Foundation
  47. Cancer Council of Victoria
  48. Stanley Medical Research Foundation
  49. MBF
  50. NHMRC
  51. Beyond Blue
  52. Rotary Health
  53. Geelong Medical Research Foundation
  54. Glaxo Smith-Kline
  55. Meat and Livestock Board
  56. Mayne Pharma
  57. Woolworths
  58. CIHR
  59. CANMAT
  60. GlaxoSmithKline
  61. Janssen
  62. Michael Smith Foundation for Health Research
  63. Sanofi
  64. SMRI
  65. Universal-CNPq
  66. CNPq/INCT-TM
  67. FIPE-HCPA
  68. Colciencias
  69. Universidad de Antioquia
  70. NIMH
  71. Abbott
  72. Glaxo SmithKline
  73. Janssen Cilag
  74. Sanofi Synthelabo
  75. [CM12/00062]

向作者/读者索取更多资源

ObjectiveWe discuss the rationale behind staging systems described specifically for bipolar disorders. Current applications, future directions and research gaps in clinical staging models for bipolar disorders are outlined. MethodWe reviewed the literature pertaining to bipolar disorders, focusing on the first episode onwards. We systematically searched data on staging models for bipolar disorders and allied studies that could inform the concept of staging. ResultsWe report on several dimensions that are relevant to staging concepts in bipolar disorder. We consider whether staging offers a refinement to current diagnoses by reviewing clinical studies of treatment and functioning and the potential utility of neurocognitive, neuroimaging and peripheral biomarkers. ConclusionMost studies to date indicate that globally defined late-stage patients have a worse overall prognosis and poorer response to standard treatment, consistent with patterns for end-stage medical disorders. We believe it is possible at this juncture to speak broadly of early'- and late'-stage bipolar disorder. Next steps require further collaborative efforts to consider the details of preillness onset and intermediary stages, and how many additional stages are optimal.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据